Fred Colen

Successfully turned CRM Division around, overcoming severe Quality and Regulatory issues and clearing FDA warning letter in 14 month time, dramatically increased operational efficiency, introduced exciting new products, sponsored landmark MADIT-CRT Clinical study, which led to new FDA indication for CRT-D treatment of early stage heart failure and achieved double digit revenue growth in 2009 and 2010 of this $2.4B global business.